Editas' share price has struggled due to clinical setbacks, but recent focus on in-vivo gene editing offers renewed hope and upside potential. The company is valued near cash levels, with $221M on ...

Liverpool’s Pursuit of Alexander Isak: Ambitious or Unrealistic? Liverpool’s ambitions in the summer market are as bold as ever following a Premier League title in Arne Slot’s debut season. With deals ...

Former Chelsea, Scotland and Hearts midfielder Pat Nevin believes that Liverpool are far from certain to finish above rivals Everton this season. With Everton set to entertain Manchester United ...